9U9 logo

Unity BiotechnologyDB:9U9 Stock Report

Market Cap €1.6m
Share Price
€0.085
My Fair Value
AN
AnalystConsensusTarget
€2.77
96.9% undervalued intrinsic discount
1Y-93.6%
7D-6.0%
Portfolio Value
View

Unity Biotechnology, Inc.

DB:9U9 Stock Report

Market Cap: €1.6m

Unity Biotechnology (9U9) Stock Overview

A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. More details

9U9 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

9U9 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Unity Biotechnology, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Unity Biotechnology
Historical stock prices
Current Share PriceUS$0.085
52 Week HighUS$2.62
52 Week LowUS$0.076
Beta0.93
1 Month Change-87.14%
3 Month Change-89.98%
1 Year Change-93.64%
3 Year Change-98.64%
5 Year Changen/a
Change since IPO-99.93%

Recent News & Updates

Recent updates

Shareholder Returns

9U9DE BiotechsDE Market
7D-6.0%2.1%-0.5%
1Y-93.6%-10.2%18.2%

Return vs Industry: 9U9 underperformed the German Biotechs industry which returned -12.4% over the past year.

Return vs Market: 9U9 underperformed the German Market which returned 19.1% over the past year.

Price Volatility

Is 9U9's price volatile compared to industry and market?
9U9 volatility
9U9 Average Weekly Movement30.4%
Biotechs Industry Average Movement7.6%
Market Average Movement5.1%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.6%

Stable Share Price: 9U9's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 9U9's weekly volatility has increased from 21% to 30% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200916n/aunitybiotechnology.com

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications.

Unity Biotechnology, Inc. Fundamentals Summary

How do Unity Biotechnology's earnings and revenue compare to its market cap?
9U9 fundamental statistics
Market cap€1.56m
Earnings (TTM)-€23.73m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.1x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9U9 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$12.06m
Gross Profit-US$12.06m
Other ExpensesUS$15.45m
Earnings-US$27.50m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.60
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 9U9 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/28 13:21
End of Day Share Price 2025/07/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Unity Biotechnology, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Andrew FeinH.C. Wainwright & Co.
Matthew CaufieldH.C. Wainwright & Co.